4-[1-(6-Methylpyridin-2-yl)-5-quinoxalin-6-yl-1,2,4-triazol-3-yl]benzonitrile | 701979-19-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-[1-(6-Methylpyridin-2-yl)-5-quinoxalin-6-yl-1,2,4-triazol-3-yl]benzonitrile
• CAS: 701979-19-3
• 化学式: C₂₃H₁₅N₇
• 分子量: 389.419
• InChiKey: SWNYATTWPSVIIW-UHFFFAOYSA-N

物化性质

• 沸点：
  682.8±65.0 °C(Predicted)
• 密度：
  1.34±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  30
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.04
• 拓扑面积：
  93.2
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  4-[1-(6-Methylpyridin-2-yl)-5-quinoxalin-6-yl-1,2,4-triazol-3-yl]benzonitrile 在 sodium hydroxide 、 双氧水 作用下， 以 乙醇 、 水 为溶剂， 反应 3.0h， 以64%的产率得到4-[1-(6-methyl-pyridin-2-yl)-5-quinoxalin-6-yl-1H-[1,2,4]triazol-3-yl]-benzamide
  参考文献：
  名称：

  Design, synthesis, and biological evaluation of novel 2-pyridinyl-[1,2,4]triazoles as inhibitors of transforming growth factor β1 type 1 receptor

  摘要：

  A series of 2-pyridinyl-[1,2,4]triazoles have been synthesized and evaluated for their ALK5 inhibitory activity in the luciferase reporter assays. Compound 12b showed significant ALK5 inhibition (SBE-Luciferase, 73%; p3TP-Luciferase, 85%) at a concentration of 5 muM that is comparable to that of SB-431542 (SBE-Luciferase, 79%; p3TP-Luciferase, 88%), but weak p38alpha MAP kinase inhibition (4%) at a concentration of 10 muM that is much lower than that of SB-431542 (54%). The binding mode of 12b generated by flexible docking studies revealed that the structure of 12b is a good fit into the (NPC-30345)-binding cavity of ALK5. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2004.03.004
• 作为产物：
  描述：

  对苯二腈 在 4-二甲氨基吡啶 、 三乙胺 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 34.0h， 生成 4-[1-(6-Methylpyridin-2-yl)-5-quinoxalin-6-yl-1,2,4-triazol-3-yl]benzonitrile
  参考文献：
  名称：

  Design, synthesis, and biological evaluation of novel 2-pyridinyl-[1,2,4]triazoles as inhibitors of transforming growth factor β1 type 1 receptor

  摘要：

  A series of 2-pyridinyl-[1,2,4]triazoles have been synthesized and evaluated for their ALK5 inhibitory activity in the luciferase reporter assays. Compound 12b showed significant ALK5 inhibition (SBE-Luciferase, 73%; p3TP-Luciferase, 85%) at a concentration of 5 muM that is comparable to that of SB-431542 (SBE-Luciferase, 79%; p3TP-Luciferase, 88%), but weak p38alpha MAP kinase inhibition (4%) at a concentration of 10 muM that is much lower than that of SB-431542 (54%). The binding mode of 12b generated by flexible docking studies revealed that the structure of 12b is a good fit into the (NPC-30345)-binding cavity of ALK5. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2004.03.004